Respreeza (human alpha-1-proteinase inhibitor): Sterility issue with the infusion device co-packed with Respreeza 4.000 mg and 5.000 mg

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Respreeza
Active substance
Human alpha1-proteinase inhibitor
Therapeutic area (MeSH)
  • Genetic Diseases, Inborn
  • Lung Diseases
Procedure number
EMEA/H/C/002739
DHPC type
Medicine shortage
Human ATC code
B02AB02
Dissemination date
26/03/2021

How useful was this page?

Add your rating